AstraZeneca ended a Phase 3 study of volrustomig, a lung cancer therapy it was evaluating in combination with chemotherapy, after an interim data check suggested survival goals would likely be missed. The company said the Independent Data Monitoring Committee recommended stopping following a planned review of trial data. The decision adds to a sequence of late-stage setbacks for AstraZeneca’s oncology pipeline, intensifying scrutiny on whether its next-generation lung cancer strategies can deliver durable improvements. AstraZeneca did not indicate a new timeline in the report, but the termination removes volrustomig from further confirmatory execution. For competitors and partners, the trial stop reduces the near-term competitive threat from a multi-pathlung cancer regimen, while leaving AstraZeneca’s continued development focus on other late-stage assets.